Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Accrufer (ferric maltol) is indicated for the treatment of iron deficiency in adults.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Intravenous ferric carboxymaltose is likely superior to intravenous iron sucrose in increasing hemoglobin in patients with iron deficiency anemia, with a responder rate of 150/244 compared to 118/239 (RR 1.25, 95% CI 1.06 to 1.46, NNTB = 9).
• Oral ferric maltol is likely more effective than placebo in increasing hemoglobin, with responders being 36/64 for ferric maltol versus 0/64 for placebo (RR 73.00, 95% CI 4.58 to 1164.36).
• Intravenous iron preparations generally result in more hemoglobin responders compared to oral preparations, with responder rates of 368/554 versus 205/373 (RR 1.17, 95% CI 1.05 to 1.31, NNTB = 11).
• Withdrawals due to adverse events may be higher in oral iron preparations compared to intravenous iron preparations (15/554 vs. 31/373, RR 0.39, 95% CI 0.20 to 0.74).
• No significant differences in serious adverse events were observed among the different treatment arms, but the certainty of the evidence was very low due to the low number of reported events.
• There is no population types or subgroups information available in the reviewed studies.